Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IUGNF Relative to the S&P 500

IUGNF Relative to the Sector

Seasonal Chart Analysis

Analysis of the Imugene Ltd. (OTCMKT:IUGNF) seasonal charts above shows that a Buy Date of October 17 and a Sell Date of January 22 has resulted in a geometric average return of 77.33% above the benchmark rate of the S&P 500 Total Return Index over the past 5 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 5 years by an average of 93.82% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 5 years of data is available for shares of IUGNF, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

To download IUGNF seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IUGNF